|
Name |
Chaetoviridin E
|
Molecular Formula | C23H23ClO5 | |
IUPAC Name* |
(6aS)-5-chloro-6a-methyl-9-[(E)-2-methylbut-2-enoyl]-3-[(E,3S)-3-methylpent-1-enyl]furo[2,3-h]isochromene-6,8-dione
|
|
SMILES |
CC[C@H](C)/C=C/C1=CC2=C(C(=O)[C@@]3(C(=C(C(=O)O3)C(=O)/C(=C/C)/C)C2=CO1)C)Cl
|
|
InChI |
InChI=1S/C23H23ClO5/c1-6-12(3)8-9-14-10-15-16(11-28-14)18-17(20(25)13(4)7-2)22(27)29-23(18,5)21(26)19(15)24/h7-12H,6H2,1-5H3/b9-8+,13-7+/t12-,23-/m0/s1
|
|
InChIKey |
XEBNYZYYHZZSJR-IIWQDEIUSA-N
|
|
Synonyms |
Chaetoviridin E; CHEBI:67614; Chaetoviridine E; CHEMBL1802154; Q27136081; (6aS)-5-chloro-6a-methyl-9-[(2E)-2-methylbut-2-enoyl]-3-[(1E,3S)-3-methylpent-1-en-1-yl]-6H-furo[2,3-h]isochromene-6,8(6aH)-dione; (6aS)-5-chloro-6a-methyl-9-[(E)-2-methylbut-2-enoyl]-3-[(E,3S)-3-methylpent-1-enyl]furo[2,3-h]isochromene-6,8-dione
|
|
CAS | NA | |
PubChem CID | 25108108 | |
ChEMBL ID | CHEMBL1802154 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 414.9 | ALogp: | 4.2 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 69.7 | Aromatic Rings: | 3 |
Heavy Atoms: | 29 | QED Weighted: | 0.357 |
Caco-2 Permeability: | -4.791 | MDCK Permeability: | 0.00001850 |
Pgp-inhibitor: | 0.859 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.48 |
30% Bioavailability (F30%): | 0.498 |
Blood-Brain-Barrier Penetration (BBB): | 0.255 | Plasma Protein Binding (PPB): | 81.80% |
Volume Distribution (VD): | 2.251 | Fu: | 8.92% |
CYP1A2-inhibitor: | 0.968 | CYP1A2-substrate: | 0.68 |
CYP2C19-inhibitor: | 0.963 | CYP2C19-substrate: | 0.252 |
CYP2C9-inhibitor: | 0.942 | CYP2C9-substrate: | 0.033 |
CYP2D6-inhibitor: | 0.97 | CYP2D6-substrate: | 0.01 |
CYP3A4-inhibitor: | 0.97 | CYP3A4-substrate: | 0.268 |
Clearance (CL): | 3.075 | Half-life (T1/2): | 0.196 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.964 |
Drug-inuced Liver Injury (DILI): | 0.968 | AMES Toxicity: | 0.906 |
Rat Oral Acute Toxicity: | 0.951 | Maximum Recommended Daily Dose: | 0.941 |
Skin Sensitization: | 0.946 | Carcinogencity: | 0.943 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.049 |
Respiratory Toxicity: | 0.963 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001874 | 0.736 | D0C1SF | 0.212 | ||||
ENC002010 | 0.733 | D0WY9N | 0.212 | ||||
ENC004761 | 0.708 | D0O6KE | 0.202 | ||||
ENC003626 | 0.654 | D02GAC | 0.189 | ||||
ENC004762 | 0.654 | D0R6RC | 0.188 | ||||
ENC002613 | 0.608 | D0E9KA | 0.185 | ||||
ENC004682 | 0.598 | D0F4ZY | 0.183 | ||||
ENC005420 | 0.577 | D06FVX | 0.180 | ||||
ENC002612 | 0.563 | D0WN0U | 0.179 | ||||
ENC001841 | 0.531 | D07ESC | 0.179 |